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Introduction
RNA interference (RNAi) is the standard method to suppress 
gene expression because of its target specificity, potency, and 
ability to silence the expression of virtually any gene. Using 
a small interfering RNA (siRNA),1 which comprises a 21-mer, 
is the general approach used to induce RNAi because it can 
be easily prepared using a DNA/RNA synthesizer. Synthetic 
siRNA can be chemically modified to increase the potency 
of RNAi activity and to abrogate the innate immune stimu-
lation.2,3 Accordingly, siRNAs have been used as biologi-
cal tools and new drug candidates.4 Plasmid DNA (pDNA) 
expressing short hairpin RNA (shRNA) can also be used 
to induce RNAi.5–8 pDNA produces numerous shRNAs that 
induce RNAi with potent and long-term RNAi activity, even 
if only one pDNA molecule is delivered to the nucleus. How-
ever, it has some drawbacks in therapeutic use, such as low 
pDNA transfection efficiency arising from its huge molecular 
size and innate immune responses induced by extra genes, 
such as CpG motifs.9–12 To overcome these drawbacks, 
 minimally-sized plasmid vectors transcribing shRNAs have 
been developed.13–15 These vectors effectively suppress tar-
geted gene expression in vitro. To the best of our knowledge, 
there are no reports of their use in vivo. Moreover, it is unclear 
whether pDNA downsizing itself can diminish the innate 
immune responses leading to systematic adverse effects.
Meanwhile, our groups have explored a series of 
 4′-thionucleic acids with sulfur atoms at the 4′-position 
instead of oxygen atoms. We reported that both 4′-thioRNA 
and 4′-thioDNA exhibit not only increased hybridization and 
nuclease resistance compared with unmodified  molecules16–18 
but are biologically equivalent to naturally occurring RNA and 
DNA because sulfur and oxygen atoms belong to the same 
group in the periodic table. Thus, a series of 4′-thioRNAs were 
utilized as siRNAs in gene silencing via RNAi19–21 and/or anti-
microRNA oligonucleotides.22,23 Concerning 4′-thioDNA, we 
could amplify a highly modified 4′-thioDNA using 2′-deoxy-4′-
thionucleoside 5′-triphosphates (dSNTPs),15,24 and we used 
the polymerase chain reaction (PCR)- amplified 4′-thioDNA 
products as templates to synthesize natural RNAs in vitro.15,25 
These results prompted us to develop a new artificial DNA 
device to produce RNAi inducers, that we call the intelli-
gent shRNA expression device (iRed), which is composed 
of 4′-thioDNA (Figure 1). If shRNAs are transcribed from 
the iRed, similar to natural dsDNA, RNAi activities should 
be expected. Further, we predicted that the iRed prevents 
undesired immune responses due to the synergistic effect 
of downsizing and chemical modifications using 2′-deoxy-4′-
thioribonucleoside units as  chemically-modified siRNA did. 
Here we describe the development of the iRed as an alter-
native producer of shRNA and show that the shRNAs tran-
scribed from iRed in HeLa cells silenced gene expression. 
We succeeded in inducing RNAi using an iRed in mice with-
out inducing a detectable innate immune response.
Results
Construction of iRed consisting of 4′-thioDNA
We first attempted the construction of iRed. As shown in 
Figure 1, the iRed contained only an shRNA transcriptional 
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The development of a versatile technique to induce RNA interference (RNAi) without immune stimulation in vivo is of interest as 
existing approaches to trigger RNAi, such as small interfering RNA (siRNA) and plasmid DNA (pDNA) expressing short hairpin 
RNA (shRNA), present drawbacks arising from innate immune stimulation. To overcome them, an intelligent shRNA expression 
device (iRed) designed to induce RNAi was developed. The minimum sequence of iRed encodes only the U6 promoter and 
shRNA. A series of iRed comprises a polymerase chain reaction (PCR)-amplified 4′-thioDNA in which any one type of adenine 
(A), guanine (G), cytosine (C), or thymine (T) nucleotide unit was substituted by each cognate 4′-thio derivatives, i.e., dSA iRed, 
dSG iRed, dSC iRed, and ST iRed respectively. Each modified iRed acted as a template to transcribe shRNA with RNAi activity. 
The highest shRNA yield was generated using dSC iRed that exerted gene silencing activity in an orthotopic mouse model 
of mesothelioma. Reducing the minimal structure required to transcribe shRNA and the presence of the 4′-thiomodification 
synergistically function to abrogate innate immune response induced by dsDNA. The iRed will introduce a new approach to 
induce RNAi without inducing a detectable innate immune response.
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unit encoded by the pDNA, which comprised the promoter 
and shRNA coding sequences. In our previous study, we 
reported PCR amplification in the presence of each dSNTP 
that generated 104 base pairs (bp) of double-stranded (ds) 
4′-thioDNA.24 Using similar PCR conditions and one type 
of dSNTP to substitute the cognate dNTP, the sequences 
encoding the U6 promoter and an shRNA specific for pGL2 
firefly luciferase (Fluc) were amplified to produce a series of 
iReds as follows: dSA iRed, dSG iRed, ST iRed, and dSC 
iRed (Supplementary Figure S1a). The size of the iRed with 
4′-thiomodification was 362 bp compared with 6,503 bp of the 
parental pDNA. The incorporation of 209 residues of 2′-deoxy-
4′-thioadenosine (dSA) into dSA iRed and of 212 residues of 
ST in ST iRed were required in every PCR cycle. In contrast, 
113 and 118 residues of dSG in dSG iRed and dSC in dSC 
iRed were incorporated, respectively. However, there was 
no correlation between the PCR amplification yields and the 
number of incorporated 4′-thionucleoside residues (Supple-
mentary Figure S1). Although dSG iRed and dSC iRed con-
tained similar numbers of  4′-thiomodifications, the latter was 
the most efficient. The preparation of an iRed with greater than 
two types of 4′-thio units was also attempted but was unsuc-
cessful because the iRed sequence was much longer com-
pared with that of a 104 bp template that we previously used 
(data not shown).24 Therefore, we decided to use 4′-thioD-
NAs containing one type of  2′-deoxy-4′-thionucleoside unit to 
produce the iReds.
The iRed suppressed target gene expression via RNAi 
machinery in HeLa cells
To evaluate in vitro gene silencing activity, the resulting 
iReds specific for pGL2 Fluc were cotransfected with pGL2 
Fluc and Renilla luciferase (Rluc) pDNAs into HeLa cells. In 
Figure 2a, the gene silencing activities of each iRed at 24, 
48, and 72 hours post-transfection are shown with those of 
pDNA, synthetic shRNA, and PCR-amplified natural dsDNA 
having the same sequence as the iRed (called the natural 
device). pDNA had a high potency and continued to suppress 
pGL2 Fluc gene expression by 95% from 24 to 72 hours 
Figure 1  Schematic of gene silencing using an intelligent 
shRNA expression device (iRed). Step1: A region of plasmid 
DNA (pDNA) encoding the U6 promoter and a short hairpin RNA 
(shRNA) was amplified using PCR in the presence of one type of 
2’-deoxy-4’-thionucleoside triphosphate (dSNTP) and three other 
dNTPs to synthesize an iRed. Step 2: The iRed was delivered into 
the nucleus. Step 3: Numerous shRNAs were transcribed from the 
iRed to possess a potent RNA interference (RNAi) activity.
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post-transfection into HeLa cells at 1.0 nmol/l. Under equi-
molar conditions, shRNA reduced target gene expression, 
although its potency was less than that of pDNA. The iReds 
suppressed pGL2 Fluc gene expression with different efficien-
cies depending on the variations in the  4′-thiomodification. 
The dSA iRed and ST iRed, having more than 200 units of 
4′-thionucleotide in their sequences, showed moderate activ-
ities, which increased over time post-transfection. In contrast, 
the dSG iRed and dSC iRed having approximately 100 units 
of 4′-thionucleotide strongly silenced luciferase gene expres-
sion even at 24 hours post-transfection; their activities were 
maintained up to 72 hours post-transfection. The RNAi activi-
ties of the dSG iRed and dSC iRed were more potent than 
those of synthetic shRNA. The most potent RNAi activity was 
observed when the dSC iRed was used.
To further validate that iReds reduced target gene expres-
sion via RNAi, the amounts of shRNAs transcribed from each 
iRed were determined using reverse-transcription quantita-
tive PCR (Figure 2b).26 The natural device acted as a genetic 
template to produce shRNA. Similarly, the iReds consisting 
of 4′-thioDNA also yielded shRNA, although their amounts 
were less than those of the natural device at 24 hours 
 post-transfection. However, continued monitoring revealed 
that the amounts of shRNAs transcribed from the iReds 
increased over time post-transfection up to 72 hours. In addi-
tion, these accretions of shRNA production could result in 
long-term RNAi activities of iReds (Figure 2a).
Theoretically, a new artificial DNA used to produce shRNA 
can suppress the expression of any gene. To validate this, 
we applied the iRed to the pGL3 Fluc target. The iReds tar-
geting pGL3 Fluc were prepared similarly to those target-
ing pGL2 Fluc by PCR in the presence of a mixture of one 
type of dSNTP and the three other dNTPs  (Supplementary 
 Figure S2), and their RNAi activities were evaluated in 
HeLa cells. All iReds containing each modification pattern 
reduced pGL3 Fluc gene expression in a dose-dependent 
manner, similar to pDNA and synthetic shRNA (Figure 3). 
Their relative potencies of RNAi activity, which may depend 
on the modification patterns, were quite similar to those 
targeting pGL2 Fluc. To examine the target specificity, the 
iReds targeting pGL2 Luc were transfected into the HeLa 
cells expressing pGL3 Luc. The iReds targeting pGL2 Luc 
did not cause a significant suppression of pGL3 Luc activity 
at 1.0 nmol/l  post-transfection. This indicates that our new, 
artificial DNA can suppress target gene expression with high 
specificity, even in a highly homologous gene expression 
 (Supplementary Figure S3).
The RNA polymerase III-dependent RNA transcription is 
initiated at the U6 promoter sequence and terminated at the 
small polyT transcription terminator.27 Accordingly, shRNAs 
having poly(U) sequences longer than five nucleotides are 
not transcribed using U6-promoter transcription system. To 
ensure that this termination in RNA polymerase  III-dependent 
transcription was conserved even in case of 4′-thioDNA in 
the iRed, we prepared another series of iReds with a poly(U) 
stretch in the middle of the shRNA coding regions, which 
targeted pGL3 Fluc (Supplementary Figure S4). We com-
pared their RNAi activities with those of pDNA, the natural 
device, and synthetic shRNA (Figure 4) and found that none 
of the modified iReds reduced Fluc activity. Contrary to our 
expectations, we found that the pDNA silenced pGL3 Fluc 
gene expression, similar to shRNA, indicating that a sys-
tematic adverse effect caused off-target silencing. Our strat-
egy to induce RNAi using iReds showed highly conserved 
sequence-specific RNAi activity.
The iRed consisting of 4′-thioDNA acted as genetic 
template for transcribing shRNA even in vivo
Our in vitro studies showed that the iReds have great poten-
tial to induce RNAi silencing compared with synthetic shRNA 
against both pGL2 and pGL3 Fluc. To determine silencing 
activity in vivo, the gene silencing efficacy of dSC iRed tar-
geting pGL3 Fluc (Supplementary Figure S2) was evalu-
ated using an orthotopic malignant pleural mesothelioma 
mouse model. The malignant pleural mesothelioma mouse 
Figure 3 Dose-dependent RNAi activities of iReds targeting 
pGL3 Fluc compared with those of the pDNA, synthetic shRNA, 
and natural device. HeLa cells were transfected with all samples 
at the indicated concentrations. Error bars indicate the standard 
deviations of three independent experiments.
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model was prepared by injecting human pleural mesotheli-
oma cells (MSTO-211H) expressing Fluc (MSTO-211H-Luc) 
into the left pleural cavity of BALB/c nu/nu mice. Tumor devel-
opment was monitored using in vivo imaging system (IVIS). 
On days 8 and 11 after the cells were inoculated, the model 
mice were intrapleurally injected with equimolecular amounts 
of the natural device, negative control dsDNA (NC dsDNA), 
dSC iRed, or synthetic shRNA each specific for pGL3 Fluc 
as a complex with a transfection reagent designed for use 
in vivo. On days 7, 10, and 13 after the inoculation, we used 
IVIS to determine the luciferase activities of pleural tumors.
The bioluminescence of the pleural cavities of untreated 
control mice was the highest on day 13 after inoculation, indi-
cating aggressive growth of the inoculated cells (Figure 5a,b). 
Similar luciferase activities were detected that localized 
with the pleural tumors of mice injected with NC dsDNA or 
shRNA. In contrast, the dSC iRed as well as natural device 
markedly suppressed luciferase activity to approximately the 
same extent, altough a statistical significance of difference 
was not recognized between a control group/administration 
groups, because of slightly high value of standard deviation 
in a control group. Furthermore, as shown in Figure 5c, the 
mice in all tested groups did not show a significant decrease 
in body weight, indicating that the treatment samples con-
taining the dSC iRed had less systemic adverse effects fol-
lowing intrapleural administration.
Scarcely did the administration of iRed induce innate 
immune stimulation in vivo
As described in the Introduction, the iReds would have a 
great advantage not only in inducing RNAi but also in abro-
gating undesired immune stimulation. The development of a 
versatile technique for inducing RNAi without immune stim-
ulation in vivo is of great interest because approaches for 
RNAi therapeutics using pDNA present issues arising from 
immune stimulation.9–12
Figure 5 In vivo evaluation of RNAi activities. Mice that served as an orthotopic model of malignant pleural mesothelioma were 
intrapleurally administered two doses of either the natural device, negative control dsDNA (NC dsDNA), iRed, or synthetic shRNA once every 
3 days. On days 7, 10, and 13 after inoculation, the bioluminescence of the pleural cavities was observed using an in vivo imaging system. 
(a) Bioluminescence intensities. (b) Time course of RNAi activity of each sample. Data are expressed as the mean of relative photon counts 
to that of the initial (%). (c) The body weights of the mice were determined from day 7 to 13 after inoculation of the transfected cells. Data 
are represented as the mean of % initial body weight ± standard deviation. The arrows indicate the administration of samples. The error bars 
indicate the standard deviation of three or more independent experiments.
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Therefore, we next determined whether the iReds induced 
an immune response. For this purpose, we used BALB/c 
mice injected intravenously with of 20 µg of pDNA, natural 
device, ST iRed, or dSC iRed complexed with PEGylated 
cationic liposomes (lipoplex) to improve blood circulation 
time and exposure to cells. The average diameters and 
ζ-potentials of the PEGylated lipoplexes containing iReds 
with 4′-thioDNA were not significantly different from those 
that contained the natural device (Supplementary Table S3). 
At 4 hours after injection, proinflammatory cytokines (TNF-α, 
IL-6, and INF-γ) and type-I interferon (INF-α) induction lev-
els in the serum were evaluated. pDNA treatment intensely 
stimulated immune responses in TNF-α, IL-6, or INF-γ, and 
INF-α (Figure 6). Similarly, the natural device showed mod-
erate cytokine levels, indicating that only pDNA downsizing 
could not completely abrogate innate immune stimulation. 
In particular, similar levels of INF-α were induced by the nat-
ural device and pDNA. In contrast, dSC iRed and dST iRed 
induced lower levels of these cytokines, although they also 
contained CpG motifs. We therefore conclude that the down-
sizing and 4′-thiomodification synergized to abrogate the 
innate immune response to pDNA. Thus, the innate immune 
systems of these mice distinguished 4′-thioDNA from natural 
DNA when dC or T nucleotides were substituted by corre-
sponding 2′-deoxy 4′-thionucleotide.
Discussion
The pDNA expressing shRNA in cells, that induce long-term 
RNAi activity, has become an important and widely used 
approach in biological studies. However it still presents some 
drawbacks arising from innate immune response toward the 
therapeutic use. To overcome them, we explored RNAi gene 
silencing using iReds consisting of 4′-thioDNA. PCR ampli-
fication including one type of dSNTP produced c.a. 360 bp 
4′-thioDNAs encoding the U6 promoter and a shRNA cor-
responding to that of the iRed, indicating that the 4′-thioDNA 
was a good substrate for a DNA polymerase in vitro. In this 
way, the downsizing and chemical modification of iRed were 
achieved in one pot. In our examination, there was no cor-
relation between the PCR amplification yields and number 
of incorporated  4′-thionucleoside residues (Supplementary 
Figure 6 Evaluation of innate immune response induced by PEGylated lipoplexes each containing 20 µg of the pDNA, natural device, 
ST iRed, or dSC iRed. Induction levels of (a) TNF-α, (b) IL-6, (c) INF-γ, and (d) INF-α. Each sample was designed to transcribe a shRNA targeting 
pGL2 Fluc. Four hours after intravenous injection, the serum level of each molecular was determined using an enzyme-linked immunosorbent 
assay. Error bars indicate the standard deviations of three independent experiments. The P values indicate the statistical difference between the 
mice treated with pDNA and the mice treated with natural device, ST iRed or dSC iRed. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure S1b,c). Further investigations will be required to 
determine the superiority of the incorporation of each dSNTP 
and optimize the PCR conditions in the presence of more 
than two types of dSNTPs.
The transfection of HeLa cells with equimolar amounts of 
each Fluc-specific iRed suppressed luciferase expression 
more potently compared with a synthetic shRNA (Figures 2 
and 3). HeLa cells transfected with dSC iReds yielded rela-
tively large quantities of shRNA (Figure 2b). Although the 
amounts of shRNAs yielded from dSC iReds were less than 
that of natural device, the RNAi activity of dSC was equal to 
that of natural device because RNA-induced silencing com-
plexes (RISCs) are recycled and proceed through several 
rounds of mRNA cleavage events. We considered that the 
amount of shRNA yielded from dSC iRed was proper, but that 
from natural device might be surplus. These results indicate 
that 4′-thioDNA could act as an artificial genetic template to 
synthesize naturally occurring RNA in organisms. In addition, 
careful evaluation revealed that the sequences of iRed were 
exactly recognized by RNA polymerase III of mammalian 
cells to obtain highly specific RNAi activity (Figure 4). Fur-
thermore, dSC iRed exerted potent RNAi activities even in 
an orthotopic mouse model of mesothelioma without detect-
able systematic adverse effects, whereas synthetic shRNA 
showed no silencing activities under the equimolar conditions 
(Figure 5).
There are several reports evaluating transcriptional pro-
cess using chemically-modified DNAs used to transfect cell 
lines or bacteria. For example Krueger et al.28 used a DNA 
having some size-expanded unnatural base pair (xDNA) and 
demonstrated that the endogenous enzymes of Escherichia 
coli accurately transcribe xDNA. Birts et al. found that DNA 
with one unnatural triazole linkage directs the transcription 
of mRNAs in eukaryotic cells.29,30 However, there are no 
report of a sugar modified DNA template. To the best of our 
knowledge, the present study is the first to show that a highly 
chemical-modified DNA, dSC iRed, encoded a naturally 
occurring RNA that exhibited a high level of gene silencing 
activity in a mouse model.
Furthremore, the administration of dSC iRed or ST iRed 
did not induce a detectable innate immune response in vivo, 
although the natural device with the same sequence as the 
iRed induced the production of proinflammatory cytokines 
and a type-I interferon. In the case of siRNAs, the incorpo-
ration of chemical modifications, particularly 2′-O-methyl 
(2′-OMe) derivatives, prevent innate immune responses.31,32 
However, it is difficult to modify the pDNA structure. Thus, 
we reasoned that an iRed with 4′-thioDNA may provide a 
versatile approach to prepare noninflammatory shRNAs in 
organisms.
The sequence of the natural device encoding the U6 pro-
moter and shRNA still contained CpG motifs having the gen-
eral formula RRCGYY (where R and Y represent a purine and 
a pyrimidine, respectively),33 although the length is approxi-
mately 5% of that of pDNA. Therefore, the natural device 
would intensely induce innate immune response. The toll-like 
receptor 9 (TLR9) plays a critical role in immune stimulation 
triggered by dsDNA that harbors CpG motifs.34 The crys-
tal structure of the complex between TLR9 and  CpG-DNA 
reveals the CpG sequence and phosphate backbones that 
are recognized by TLR9.35 The conformational changes in 
the sugar ring caused by the substitution of O4′ with sulfur 
may result in the loss of recognition of the iRed–4′-thioDNA 
through the interaction of TLR9 with the phosphate back-
bone. Moreover, we have reported that 4′-thioDNA forms an 
A-form-like duplex structure, whereas natural DNA forms a 
B-form duplex structure.18 This higher-order structural change 
may affect recognition of the DNA by the innate immune sys-
tems of mice. It is not clear whether 4′-thioDNA acts as an 
antagonist of TLR9 or is not recognized by TLR9. However, 
these results suggest a strategy to avoid the induction of an 
innate immune response by DNAs.
In conclusion, our study showed that the 4′-thioDNA iRed 
acted as a bioisostere of the natural DNA template for DNA 
polymerase and RNA polymerase III to synthesize shRNA 
that exhibited potent gene-silencing activity. Our study is the 
first to demonstrate that a highly substituted artificial DNA 
acts as a template both for replication and transcription. The 
lack of immunogenicity of an iRed indicates its potential as 
an RNAi therapeutic. Theoretically, the 4′-thoDNA may serve 
as an artificial template to synthesize not only shRNA but 
also other functional RNAs, such as micro-RNA and mRNA 
for translation. Further studies to address these concerns are 
currently under way. Details of these results will be published 
elsewhere.
Materials and methods
General. Natural dNTPs were purchased from GE Health-
care Japan (Tokyo, Japan).  2′-Deoxy-4′-thionucleoside 
triphosphates (dSNTPs) were prepared according to our 
previous reports.15,24 Oligonucleotides were purchased from 
FASMAC (Kanagawa, Japan).  1,2-Dioleoyl-sn-glycero- 
3-phosphoethanolamine,  1,2-distearoyl-sn-glycero- 
3 -phosphoethano lamine-n- [methoxy-(PEG)-2000] 
(mPEG2000-DSPE), and 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine were generously donated by the NOF 
Corporation (Tokyo, Japan). The animal and ethics review 
committee of Tokushima University approved the experi-
ments using mice.
Construction of shRNA expression pDNA. Oligonucleotides 
having shRNA and terminator coding sequences were 
ligated into the BamHI and EcoRI sites of an shRNA expres-
sion cassette containing the U6 promoter (RNAi-Ready 
pSIREN-RetroQ, Clontech, Mountain View, CA) according to 
the manufacturer’s instructions. The inserted sequences are 
summarized in Supplementary Table S1.
Preparation of an intelligent shRNA expression device (iRed) 
and the natural device. The iReds were prepared using the 
shRNA expression pDNA as a template for PCR as follows. 
The sequences encoding the U6 promoter and shRNA in 
pDNA were amplified in 20 µl of KOD buffer containing KOD 
Dash DNA polymerase (0.05 unit/µl, TOYOBO, Osaka, Japan), 
pDNA template (0.1 fmol/µl), 200 µmol/l dNTPs, and 0.5 
µmol/l of primers. The reaction mixture was gently vortexed, 
and the DNA was amplified using a thermal cycler. PCR was 
performed under the following conditions: initial denaturation 
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at 94 °C for 15 seconds, 15 cycles of  denaturation/ampli-
fication (94 °C, 30 seconds; 62 °C, 30  seconds; 72 °C, 
30 seconds), and final extension at 72 °C for 15  minutes. 
Amplicons were purified using 1% agarose gel electropho-
resis, and the DNAs were further purified using a High Pure 
PCR Product Purification Kit (Roche, Basel,  Switzerland) and 
used as templates for the next round of PCR. The second 
PCR amplification was performed in 100 µl of reaction buffer 
containing KOD Dash DNA polymerase (0.1 unit/µl), a tem-
plate (0.2 fmol/µl), 200 µmol/l of a nucleoside  5′-triphosphate 
mixture containing one type of dSNTP and three types of 
dNTPs, and 1.25 µmol/l of primers. The reaction mixture 
was gently vortexed, and the DNA was amplified using a 
 thermal cycler. PCR was performed under the following con-
ditions: initial denaturation at 94 °C for 15 seconds, 30 cycles 
of denaturation/amplification (94 °C, 30 seconds; 62 °C, 
30  seconds; 72 °C, 10 minutes), and final extension at 72 °C 
for 15 minutes. The iRed amplicons were purified using a 
High Pure PCR Product Purification Kit (Roche).
The natural device was prepared using this same protocol 
but with unmodified dNTPs.
Cell culture. HeLa cells were cultured at 37 °C in Dulbec-
co’s modified Eagle’s medium supplemented with 10% fetal 
bovine serum (BioSource International, Camarillo, CA), 100 
units/ml penicillin, and 100 µg/ml streptomycin (ICN Biomedi-
cals, Irvine, CA) in an atmosphere containing 5% CO2.
A human pleural mesothelioma cell line (MSTO-211H) 
expressing pGL3 firefly luciferase (MSTO-211H-Luc) gener-
ated by stable transfection with the firefly luciferase (Fluc) 
gene (pGL3 Basic plasmid, Promega, Madison, WI) was 
generously supplied by Dr. Masashi Kobayashi (Depart-
ment of Thoracic Surgery, Faculty of Medicine, Kyoto Uni-
versity). MSTO-211H-Luc was in RPMI-1640 medium (Wako 
Pure Chemical, Osaka, Japan) supplemented with 10% of 
 heat-inactivated fetal bovine serum (Corning, Corning, NY), 
100 units/ml penicillin, and 100 µg/ml streptomycin in an 
atmosphere containing 5% CO2 at 37 °C. The cells were reg-
ularly passaged to maintain exponential growth.
In vitro Luciferase reporter assay. HeLa cells were seeded 
in a 96-well plate (1 × 104 cells/100 µl per well) in Dulbecco’s 
modified Eagle’s medium. After incubation for 24 hours, the 
cells were cotransfected with equimolar amounts of reporter 
pDNAs (0.2 µg per well, pGL2-control or pGL3-control, and 
pRL-TK; Promega), and iRed, shRNA expression pDNA, 
synthetic shRNA, or the natural device in equimolar amounts 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s instructions. Each well contained a 
total volume of 100 µl of Opti-MEM I (Invitrogen). After incu-
bation for 1 hour at 37 °C, the medium was replaced with 100 
µl of flesh culture medium containing 10% serum, and the 
cells were incubated at 37 °C. The cells were washed with 
phosphate-buffered saline and lysed with Passive Lysis Buf-
fer (Promega) at the indicated times after transfection, and 
Fluc and Renilla luciferase (Rluc) activities of the cell lysates 
were measured using the Dual-Luciferase Reporter Assay 
System (Promega) with an Infinite 200 PRO (TECAN, Män-
nedorf, Switzerland) according to the manufacturer’s instruc-
tions. Fluc signals were normalized to those of Rluc. The 
results were expressed as the Fluc/Rluc ratios compared 
with those of untreated cells. All experiments were performed 
in triplicate, and the data represent the mean values from at 
least three assays.
Quantification of shRNA in HeLa cells. The iRed or natural 
device (1.0 nmol/l each) was used to transfect the HeLa cells 
in the presence of Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s instructions. At the indicated times after 
transfection, the cells were washed with phosphate-buffered 
saline, and small RNAs were isolated and resuspended in 
50 µl of elution buffer using a mirVana miRNA Isolation Kit 
(Ambion, Foster City, CA) according to the manufacturer’s 
protocol. Reverse transcription reactions were performed in 
25 µl of First Standard Buffer containing an annealed specific 
primer (0.05 µmol/l) and extracted small RNAs (2.0 µmol/l/
total 50 µl) mixture, dNTPs (1.0 mmol/l), Super Script III (2.5 
unit/µl, Invitrogen), dithiothreitol (8.5 µmol/l), and RNaseOUT 
(0.1 unit/µl, Invitrogen). The cDNAs were synthesized as 
 follows: 16 °C for 30 minutes; 60 cycles of synthesis (30 °C, 
30 seconds; 42 °C, 30 seconds; 50 °C, 1 minute); and 85 °C 
for 15 minutes.26 Next, quantitative PCR reactions were per-
formed in 20 µl of reaction mixture containing FASTStart Uni-
versal Probe Master (Rox) (Roche), Universal Probe Library 
(#21) (Roche), and primers (each 900 nmol/l) using a Ste-
pOnePlus Real-Time PCR System (Applied Biosystems). The 
reaction was performed under the following conditions: initial 
denaturation at 95 °C for 10 minutes, 40 cycles at 95 °C for 
10 seconds, and 60 °C for 1 minute. The data are expressed 
as shRNA/mGAPDH. All experiments were performed in trip-
licate, and the data were analyzed using StepOne Software 
v2.1 (Applied Biosystems, Waltham, MA). Primers sequences 
are summarized in Supplementary Table S2.
Preparation of an orthotopic mouse model of mesothelioma. 
BALB/c nu/nu mice (male, 5 weeks old), which were pur-
chased from Japan SLC (Shizuoka, Japan) were allowed free 
access to water and mouse chow and were housed under a 
constant temperature, humidity, and 12-hour dark–light cycle. 
An orthotopic mouse model of mesothelioma was prepared 
by the direct injection of MSTO-211H-Luc cells (1 × 106 cells 
per mouse) into the left pleural cavity of the mice. The tumor 
was monitored using an in vivo imaging system (Xenogen, 
Advanced Molecular Vision, Lincolnshire, UK). For in vivo 
imaging, the mice were intraperitoneally injected with 100 µl 
of 7.5 mg/ml D-luciferin potassium salt and were subse-
quently anesthetized using isoflurane inhalation. Three min-
utes after injection, bioluminescence was recorded using a 
charge-coupled device camera (1-minute exposure). The 
bioluminescent region of interest (ROI) was calculated and 
shown as photon counts (photons/s/cm2/steradian).
In vivo luciferase reporter assay. An orthotopic model 
mouse of mesothelioma was prepared by the inoculation of 
 MSTO-211H-Luc cells into the pleural cavity. On days 8 and 
11 after inoculation, the tumor-bearing mice (four mice per 
group) were intrapleurally injected with two doses of either 
the natural device (1 mg/kg), NC dsDNA (1 mg/kg), dSC iRed 
(1 mg/kg), or synthetic shRNA (0.077 mg/kg). Each sample 
was complexed with a transfection reagent designed for use 
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in vivo (TurboFect Transfection Reagents, Life Technologies, 
Carlsbad, CA) and used according to the manufacturer’s 
instructions. On days 7, 10, and 13 after the inoculation, the 
luciferase activity of the pleural tumor was observed using 
IVIS as described in the section “Preparation of an orthotopic 
mouse model of mesothelioma”.
Preparation of PEGylated lipoplex of iRed, pDNA, and the 
natural device. Briefly, the lipids  1,2-Dioleoyl-sn-glycero- 
3-phosphoethanolamine,  1-palmitoyl-2-oleoyl-sn-glycero-3- 
phosphocholine, cholesterol (Wako Pure Chemical), and 
 O,O’-ditetradecanoyl-N-(α-trimethylammonioacetyl)dietha-
nolamine chloride (DC-6–14, Sogo Pharmaceutical, Tokyo, 
Japan) were dissolved in chloroform and mixed at molar 
ratios of 3:2:3:2. After evaporating chloroform, the thin lipid 
films were rehydrated with 9% sucrose at 37 °C, and the sus-
pensions were sized by repeated extrusion through polycar-
bonate membrane filters (Nucleopore) with consecutive pore 
sizes of 400, 200, and 100 nm and mixed with 5 mol% of 
mPEG2000-DSPE at 37 °C. The phospholipid concentrations 
of the resulting PEGylated cationic liposomes were quanti-
fied using the Fiske and Subbarow phosphate assay.36 To 
form a lipoplex, equal volumes of PEGylated cationic lipo-
somes (1.2 µmol total lipids) and DNA solution (20 µg) were 
mixed and vortexed for 15 minutes at room temperature.
Particle size and ζ-potential measurement. Size and ζ- 
potentials were measured using a NICOMP 370 HPL submi-
cron particle analyzer (Particle Sizing System, Port Richey, 
FL). Lipoplexes were diluted with 9% sucrose, and measure-
ments were performed at 25 °C and repeated independently 
three times.
Cytokine assays. BALB/c mice (male, 5 weeks old, Japan 
SLC) were intravenously injected with 20 µg each DNA sam-
ple formulated with a lipoplex. Four hours after the injection, 
peripheral blood was collected from the retro-orbital plexus 
while the mice were anesthetized. To obtain serum, the 
blood was stored for 30 minutes at room temperature and 
then centrifuged at 3,000 rpm at 4 °C for 15 minutes. The 
serum levels of IL-6, INF-γ, and TNF-α were quantified using 
Quantikine Immunoassay Kits (R&D Systems, Minneapo-
lis, MN), and INF-α was quantified using a VeriKine Mouse 
Interferon Alpha ELISA Kit (PBL interferon source, Piscat-
away, NJ). Experiments were performed in triplicate at room 
temperature.
Statistical analysis. Differences in a group were evaluated via 
analysis of variance testing using the Tukey post-hoc test.
Supplementary material
Table S1. Sequences of ligated ODNs for construction of 
pDNAs expressing shRNAs.
Table S2. Sequences of primers used for the quantification 
of transcribed shRNA in HeLa cells.
Table S3. Physicochemical properties of PEGylated 
 iRed-lipoplex, pDNA-lipoplex and natural device-lipoplex.
Figure S1. PCR preparation of an iRed targeting pGL2 Fluc.
Figure S2. Preparation of iRed targeting pGL3 Fluc.
Figure S3. Evaluation of RNAi activities of iReds targeting 
pGL2 against pGL3 Fluc.
Figure S4. Preparation of iRed targeting pGL3 Fluc but 
having terminator sequence in the middle of shRNA coding 
region.
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